Literature DB >> 19996005

Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal.

Juan Jesús Carrero1, Peter Stenvinkel.   

Abstract

Because inflammation by now is a "traditional" finding that predicts poor outcome and cardiovascular events in the vast majority of patients with ESRD, it could be argued that inflammatory biomarkers should not longer be considered "novel" risk factors. In this review, we forward the hypothesis that, in addition to putative direct proatherogenic effects, persistent inflammation may serve as a catalyst and, in the toxic uremic milieu, modulate the effects of other concurrent vascular and nutritional risk factors. We discuss some recent observational studies, suggesting that the presence of persistent inflammation magnifies the risk for poor outcome via mechanisms related to self-enhancement of the inflammatory cascade and exacerbation of both the wasting and the vascular calcification processes. Because persistent inflammation may be the silent culprit of other commonly observed pathophysiologic alterations in chronic kidney disease, it is imperative that inflammatory markers be regularly monitored and therapeutic attempts be made to target persistent low-grade inflammation in this patient group.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19996005     DOI: 10.2215/CJN.02720409

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  69 in total

Review 1.  Predialysis chronic kidney disease in 2010: Novel targets for slowing CKD progression.

Authors:  Juan Jesús Carrero; Peter Stenvinkel
Journal:  Nat Rev Nephrol       Date:  2011-02       Impact factor: 28.314

2.  C-reactive protein variability is associated with vascular access outcome in hemodialysis patients.

Authors:  Wei-Hung Kuo; Yueh-Ting Lee; Hwee-Yeong Ng; Chun-Yeh Wang; Chien-Hsing Wu; Chien-Te Lee
Journal:  J Clin Lab Anal       Date:  2017-04-27       Impact factor: 2.352

3.  Decoy receptor 3, a novel inflammatory marker, and mortality in hemodialysis patients.

Authors:  Szu-Chun Hung; Ta-Wei Hsu; Yao-Ping Lin; Der-Cherng Tarng
Journal:  Clin J Am Soc Nephrol       Date:  2012-05-24       Impact factor: 8.237

4.  Is peritoneal dialysis causing a measurable burden of inflammatory and endothelial injury on top of metabolic syndrome?

Authors:  M Miler; N Nikolac; D Segulja; S Kackov Maslac; I Celap; K Altabas; S Sefer; A M Simundic
Journal:  J Endocrinol Invest       Date:  2016-09-06       Impact factor: 4.256

5.  Glycemic load is associated with oxidative stress among prevalent maintenance hemodialysis patients.

Authors:  Chutatip Limkunakul; Mary B Sundell; Brianna Pouliot; Amy J Graves; Ayumi Shintani; Talat A Ikizler
Journal:  Nephrol Dial Transplant       Date:  2013-12-17       Impact factor: 5.992

Review 6.  Intestinal Microbiota in Type 2 Diabetes and Chronic Kidney Disease.

Authors:  Alice Sabatino; Giuseppe Regolisti; Carmela Cosola; Loreto Gesualdo; Enrico Fiaccadori
Journal:  Curr Diab Rep       Date:  2017-03       Impact factor: 4.810

Review 7.  Does inflammation affect outcomes in dialysis patients?

Authors:  Kristen L Nowak; Michel Chonchol
Journal:  Semin Dial       Date:  2018-03-07       Impact factor: 3.455

8.  Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC.

Authors:  Jayanta Gupta; Nandita Mitra; Peter A Kanetsky; Joe Devaney; Maria R Wing; Muredach Reilly; Vallabh O Shah; Vaidyanathapura S Balakrishnan; Nicolas J Guzman; Matthias Girndt; Brian G Periera; Harold I Feldman; John W Kusek; Marshall M Joffe; Dominic S Raj
Journal:  Clin J Am Soc Nephrol       Date:  2012-09-27       Impact factor: 8.237

Review 9.  Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies.

Authors:  Wei Pan; Yongbo Kang
Journal:  Int Urol Nephrol       Date:  2017-08-28       Impact factor: 2.370

10.  Inflammatory stress promotes the development of obesity-related chronic kidney disease via CD36 in mice.

Authors:  Ping Yang; Yayun Xiao; Xuan Luo; Yunfei Zhao; Lei Zhao; Yan Wang; Tingting Wu; Li Wei; Yaxi Chen
Journal:  J Lipid Res       Date:  2017-05-23       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.